A 2025 report from nonprofit CancerCare, drawing on a national survey of 1,201 insured cancer patients, found that 95% of prior authorization requests for cancer treatment were eventually approved. What those patients lost in the process was time. Twenty-nine percent experienced diagnostic delays, 40% faced treatment delays, and those enrolled in employer-sponsored plans bore the heaviest administrative load of any insurance type. Humana, Evolent Health, and American Oncology Network (AON) are now testing a model designed to remove that friction before it starts.
The three organizations announced the launch of an oncology care model across AON community clinics in eight states. Under the arrangement, practices that demonstrate adherence to established, evidence-based treatment pathways are exempt from submitting individual prior authorization requests for most anticancer drug therapies. The model currently applies to Humana Medicare Advantage members at participating AON clinics, with Evolent providing the clinical pathway infrastructure, quality improvement programs, and provider performance reporting.
The mechanism substitutes upfront pathway alignment for case-by-case approval. Rather than reviewing individual drug requests against clinical criteria each time, the insurer pre-validates the practice’s adherence to evidence-based protocols. Practices that meet the standard get frictionless access to the therapies those protocols cover. The model also incorporates immunotherapy monitoring. Automated reminders in AON’s electronic health record system prompt periodic testing to determine whether patients are still responding to treatment, a step the press release describes as currently underused.
The CancerCare data puts the prior authorization burden in sharper focus for plan sponsors. Among respondents with employer plans, 87% faced at least one prior authorization for cancer care in the past 12 months, compared with 72% of Medicare Advantage enrollees and 57% of those on traditional Medicare. Employer plan members also reported more direct personal involvement in handling the process. Sixty-three percent said they took part in managing their own authorizations. Across the full survey, 12% of patients who got involved lost a full business week or more dealing with a single authorization incident.
The inefficiency that figure exposes is structural. A process producing 95% approval rates is not, in most cases, catching clinically inappropriate care. It is adding administrative delay to decisions that were always going to end in approval, and the burden falls disproportionately on employees covered through their workplace.
The Humana model is a Medicare Advantage initiative, but the pathway-based approach it represents is spreading across commercial insurance. Evolent launched a similar arrangement with Highmark in May 2026, beginning with medical and radiation oncology authorizations for fully insured commercial clients, with self-funded employer plan coverage following in January 2027. The underlying logic is the same: pathway adherence replaces individual approval, and practices that follow evidence-based protocols gain faster access for their patients.
“Community oncology centers are the lifeblood of the cancer treatment landscape,” said Stephen “Fred” Divers, AON’s chief medical officer. “Through this partnership, we’re bringing them the latest evidence and proven quality interventions to support their treatment decisions, while avoiding the typical friction around approvals that frustrates patients and providers.”
No outcome data or patient volume figures are included in the announcement. The model has just launched, and its impact on treatment timelines and costs has not yet been reported.
What the launch does reflect is a recognizable shift in how payers and oncology networks are trying to resolve a problem that prior authorization reform efforts have so far addressed only partially. For plan sponsors whose employees carry the highest prior authorization burden in cancer care among any insurance group, the question is whether pathway-based models will migrate from Medicare Advantage into commercial plan design quickly enough to change that picture.
